date,title,content,company
"  January 27, 2023 / 09:38 AM IST  ","Hindenburg says holds short positions in India's Adani, flags risks","Short-seller Hindenburg Research said on Wednesday it holds short positions in India's Adani Group companies through U.S.-traded bonds and non-Indian-traded derivative instruments.The seven listed companies of the Adani group, which is controlled by world's third richest man Gautam Adani, have an 85% downside on a fundamental basis due to sky-high valuations, Hindenburg said in the report.To catch all the latest updates from around the world, follow moneycontrol's LIVE blog here""Key listed Adani companies have also taken on substantial debt, including pledging shares of their inflated stock for loans, putting the entire group on precarious financial footing,"" Hindenburg said.An Adani spokesperson did not immediately respond to Reuters request for comment on the report. The company has repeatedly dismissed debt concerns.Adani Chief Financial Officer Jugeshinder Singh said on Jan. 21 ""Nobody has raised debt concerns to us. No single investor has."" Adani Enterprises, the flagship company of ports-to-energy conglomerate Adani Group, has said it will raise $2.5 billion in India's largest follow-on public offering due this Friday.Also read: Truck operators say Adani Cement’s ask is unviable; ACC dealers hurt by supply disruptions Shares of Adani Enterprises surged 125% in 2022, while other group companies, including power and gas units, rose over 100%.Adani Group's total gross debt in the financial year ending March 31, 2022, rose 40% to 2.2 trillion rupees. CreditSights, part of the Fitch Group, described the group last September as ""overleveraged"" and said it had ""concerns"" over its debt.While the report later corrected some calculation errors, CreditSights said it maintained concerns over leverage.",Adani Enterprises Ltd.
"  January 27, 2023 / 09:39 AM IST  ","Adani Group responds to Hindenburg report, calls it 'malicious'","Adani Group's Chief Financial Officer, Jugeshinder Singh, said in a statement that the company was shocked by the report, calling it a ""malicious combination of selective misinformation and stale, baseless and discredited allegations.""""The timing of the report’s publication clearly betrays a brazen, mala fide intention to undermine the Adani Group’s reputation with the principal objective of damaging the upcoming follow-on Public Offering from Adani Enterprises,"" it added.Also read: Hindenburg says holds short positions in India's Adani, flags risks""The Group has always been in compliance with all laws.""Hindenburg said its report was based on an investigation over two years that involved speaking with dozens of individuals, including former Adani Group executives as well as a review of documents.India's capital markets regulator, the Securities and Exchange Board of India, did not immediately respond to a request for comment.Adani has repeatedly dismissed debt concerns. Singh told media on Jan. 21 ""Nobody has raised debt concerns to us. No single investor has.""In the wake of the Hindenburg report, shares in Adani Ports And Special Economic Zone fell 7.3% to their lowest level since early July. Adani Enterprises dropped 3.7% to a near three-month low.Adani-owned cement firms ACC and Ambuja Cements, which it acquired from Switzerland's Holcim last year in a $10.5 billion deal, fell 7.2% and 9.7% respectively on Wednesday.Hindenburg's report said that five of seven key listed Adani companies have reported current ratios - a measure of liquid assets minus near-term liabilities - below 1. This, the short-seller said, suggested ""a heightened short-term liquidity risk"".Adani Group's total gross debt in the financial year ending March 31, 2022, rose 40% to 2.2 trillion rupees.Refinitiv data shows that debt at Adani Group's seven key listed Adani companies exceeds equity, with debt at Adani Green Energy Ltd (ADNA.NS) exceeding equity by more than 2,000%.CreditSights, part of the Fitch Group, described the group last September as ""overleveraged"" and said it had concerns about its debt. While the report later corrected some calculation errors, CreditSights said it maintained its concerns about Adani's leverage.Hindenburg is known for shorting electric truck maker Nikola Corp (NKLA.O) and Twitter though it later reversed its position in Twitter.Shares in Adani Enterprises surged 125% in 2022, while other group companies, including power and gas units, rose more than 100%.",Ambuja Cements Ltd.
"  January 29, 2023 / 07:47 PM IST  ",Hold Bajaj Auto; target of Rs 4040: Prabhudas Lilladher,"Prabhudas Lilladher's research report on Bajaj AutoWe increase our FY24/25 EPS estimates by 4% each to factor in higher ASPs and better mix. In 3QFY23, BJAUT’s EBITDA margin +180bps QoQ surprised positively driven by better USD realizations (Rs 81.7 vs Rs 75.1/79.8), superior product mix (premium segment 65% of mix vs 55% in Q2FY23) and higher mix of higher margin spares business. We remain concerned on the export side (~50% of sales) of the business given (1) currency devaluation and unavailability of USD, (2) lower affordability due to price hikes and (3) higher interest rates. Also, lack of market share gains in domestic motorcycles market over last few years, despite aggressive pricing in some segments (motorcycle market share contracted 150bps since FY19), could lead to further pricing actions and pressures on margins.OutlookHowever, we expect BJAUT’s domestic premium segment volumes to grow (similar to the industry), given stabilization in semiconductor supply. Maintain ‘HOLD’ with a target price of Rs 4,040 (Rs 3,820 earlier) at 16x Dec-24E EPS.For all recommendations report, click hereDisclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.Bajaj Auto - 27 -01-2023 - prabhu",Bajaj Auto Ltd.
"  January 29, 2023 / 07:15 PM IST  ",Hold Bajaj Auto; target of Rs 4100: ICICI Direct,"ICICI Direct's research report on Bajaj AutoBajaj Auto (BAL) is second largest motorcycle manufacturer and largest 3-W OEM domestically (FY22 market share at 18.2%, 61.5% respectively). Exports comprised ~58% of FY22 volumes; 2-W:3-W mix at ~89:11 (overall) • Strong b/s with ~Rs 15,000 crore cash on books (Dec’22 end), history of ~20% return ratios & one of the highest dividend yields among Nifty stocks.OutlookWe maintain HOLD rating on BAL following slower pace of volume recovery in export markets and gradual inching up the play in EV domain by the company with captive electric-3-W launch expected in March 2023. Introducing FY25E, we now value BAL at Rs 4,100 on SOTP basis (15x PE on FY24-25E average EPS, stake in PMAG; earlier TP: Rs 3,910).For all recommendations report, click hereDisclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.Bajaj Auto - 27 -01-2023 - ic",Bajaj Auto Ltd.
"  January 29, 2023 / 05:38 PM IST  ",Hold Bajaj Auto; target of Rs 4250: Emkay Global Financial,"Emkay Global Financial's research report on Bajaj AutoQ3 EBITDA grew by 29% YoY to Rs17.8bn, clocking 10% above our estimate due to higher revenues and gross-margin beat. Revenue increased by 3% to Rs93.2bn, coming in 3% above our estimates on better realizations and spare-part sales. Going forward, we build in 8% volume CAGR over FY23-25E (which is lower than the 11- 12% CAGR for peers such as TVSL and EIM), mainly due to higher exposure to overseas markets. Exports is likely to be under pressure in the near term, owing to weak macros, adverse currency movements and USD availability issues in the Africa, South Asia and Latin America regions. In contrast, we expect domestic volumes to grow in double-digits, driven by strong urban demand, better finance availability and favorable base effect.OutlookWe maintain HOLD on the stock, with TP of Rs4,250/share (Rs4,050 earlier), based on 17x FY25E Core EPS (Dec-24E earlier), value of investments at Rs246/share and cash reserves of Rs607/share.For all recommendations report, click hereDisclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.Bajaj Auto - 27 -01-2023 - emkay",Bajaj Auto Ltd.
"  January 27, 2023 / 10:51 PM IST  ","Buy Bajaj Auto, target of Rs 4151: Sharekhan","Sharekhan's research report on Bajaj AutoBAL reported better-than-expected operational performance for Q3FY2023, led by higher average sales realizations, improved US Dollar realization and a better product mix. The management remains positive on growth prospects in domestic markets, led by new launches, recovery in three-wheeler sales and improving industry prospects, while remaining concerned about exports in the near term. BAL is aiming to expand its EV business and indicating a launch of an electric 3-wheeler in near term.OutlookWe maintain a Buy on Bajaj Auto Limited (BAL) with an unchanged PT of Rs. 4,151, factoring sustenance of strong operating profitability. The stock is currently trading at P/E of 14.8x FY2025E EPS and 9xFY2025EV/EBIDTA.For all recommendations report, click hereDisclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.Bajaj Auto - 27 -01-2023 - khan",Bajaj Auto Ltd.
"  January 29, 2023 / 07:08 PM IST  ",Buy Cipla; target of Rs 1290: ICICI Direct,"ICICI Direct's research report on CiplaCipla is a global pharma company with over 1,500+ products in 65 therapeutic categories, with over 50 dosage forms. Indian branded formulations business accounts for ~45% of revenues and enjoys leadership in therapies like respiratory, anti-infective, cardiac, gynaecology & gastro-intestinal • Cipla derives 20% of its export revenues from the US followed by 12% from South Africa, 18% from RoW markets and 3% from APIs.OutlookWe maintain BUY due to 1) continued focus on its core strength of respiratory franchise along with other niche launches in the US (significant momentum expected from H2FY23), 2) calibrated focus on core therapies in India and 3) shift to private markets from tenderised models in other export markets. Valued at 1290 i.e. 24x P/E on FY25E EPS of Rs 52.5 + Rs 30 NPV for gRevlimid.For all recommendations report, click hereDisclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.Cipla - 27 -01-2023 - ic",Cipla Ltd.
"  January 27, 2023 / 10:50 PM IST  ","Hold Cipla, target of Rs 1158: Sharekhan","Sharekhan's research report on CiplaCipla’s Q3FY2023 numbers were in line with our expectations on revenue and EBITDA fronts but fared below expectations on a net income basis. It was largely due to higher interest and taxes. Outlook for the US business is strong with a quarterly run-rate of $195 million reached in Q3FY23 versus $175-180 million quarterly run rate reached, earlier, in Q2FY23, while the India consumer business is expected to deliver higher annual revenue of Rs. 1,100 crore by the end of FY2023 versus expectations of Rs. 600 crore of revenues guided for, before. R&D spend is likely to rise along with partnered products, which cannot support consistently higher margins, going forward, as Q3FY2023 margins were higher due to favorable products mix and strong seasonal buying in the US.OutlookWe maintain our Hold rating on Cipla, with a revised price target of Rs. 1,158 as we believe that certain high value product launches such as gAbraxane and gAdvair being deferred due to pending USFDA facility clearances, expected increase in share of partnered products, and increased R&D spend, may not support consistent margins growth, going forward.For all recommendations report, click hereDisclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.Cipla - 27 -01-2023 - khan",Cipla Ltd.
"  January 27, 2023 / 12:49 PM IST  ",Cipla: Sharp improvement in margins not likely to sustain,"                        Highlights

	Top-line growth lacks shine; however, US stands out
	Chronic therapies help underlying domestic sales 
	Elevated competition in South Africa business
	Product launches in US aid margin expansion
	Key near-term watch is traction in peptide assets
	Valuation ahead of peers

While the Q3FY23 top-line numbers were uninspiring for Cipla (CMP: Rs 1,035; Market Cap: Rs 83,560 crore), the US business stood out due to product launches. Product mix also contributed to better gross margins though its sustenance is questionable.

In the coming days, traction for peptide...
                    ",Cipla Ltd.
"  January 27, 2023 / 08:37 AM IST  ","Cipla Q3 profit up 10%, brokerages remain positive","Shares of Cipla Limited will be in focus on January 27 after the Indian pharmaceutical major posted a consolidated profit after tax (PAT) of Rs 801 crore for Oct-Dec quarter, rising by 10 percent. It had reported a profit of Rs 789 crore in the September'22 quarter.Consolidated revenue came in higher year on year by 6 percent at Rs 5,801 crore, compared to Rs 5,479 crore logged during the same period in 2021. Revenue in Q2FY23 stood at Rs 5,829 crore.Catch all the market action on our live blogHere is what brokerages have to say about stock and the company post December quarter earnings:Nirmal BangBroking house remains positive on Cipla mainly due to its strong India franchise, robust US pipeline, healthy margins and improving return ratios.The firm cut its estimates to factor in 3QFY23 performance and lower-than-expected Revlimid sales.Maintain 'Buy' on Cipla with a revised target price of Rs 1,263Prabhudas LilladherMaintain ‘Buy’ rating with revised Target Price of Rs 1,280 from Rs 1,300 earlierBroking house reduce its FY24/FY25 earnings by ~4 percent factoring in delay in key US launches and lower marginsContinue to remain positive on company’s growth across key segments including India and US given strong traction in respiratory and other portfolio, domestic formulation to potentially grow 10 percent going forward and sustainability of current US revs, backed by potential key launches.MacquarieBrokerage house has kept ‘Outperform’ rating on the stock with a target at Rs 1,235 per share as Q3 revenue/EBITDA/PAT missed estimates by 7 percent, 6 percent, 14 percent.As FY23 EBITDA margin guidance of 21 to 22 percent has been maintained, lowered the FY23/FY24/FY25 EPS estimates to 8 percent, 5 percent, 3 percent to reflect Q3 miss & delay for Advair.Current stock price is factoring in Q3 miss & Advair delay, reported CNBC-TV18.Kotak Institutional EquitiesResearch firm has kept ‘Buy’ rating on the stock with a target at Rs 1,255 per share.The steady Q3 with softness in SAGA being partially offset by strength in US & higher gross margin.Expect company’s US sales to deliver healthy 18% CAGR over FY22-25. With domestic performance stays on track, SAGA is expected to pick up Q1FY24 onwards.Kotak Institutional Equities expect Cipla to deliver robust 24% EPS CAGR over FY22-25, reported CNBC-TV18.Morgan StanleyBrokerage house has kept ‘Overweight’ rating on the stock with a target at Rs 1,336 per share.Cipla continues to enrich its US pipeline with inhalers and peptides with good visibility of 3-4 complex launches every year for next 3 years, reported CNBC-TV18.Jefferies Broking house has maintained ‘Hold’ rating on the stock with a target at Rs 1,100 per share.The Q3 numbers missed revenue/EBITDA estimates by 6 percent on revenue decline in SAGA & muted growth in India.US was strong on back of seasonality & market share gains in key products, while India & SAGA growth should recover.The high impact US launches for FY24 have been delayed, poses downside risk to consensus estimates, reported CNBC-TV18.Expect 18 percent EPS CAGR over FY23-25E given resilient earnings, improving US visibility and strong free cash flow generation.Disclaimer: The views and investment tips expressed by experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.",Cipla Ltd.
"  January 29, 2023 / 05:35 PM IST  ",Hold Dixon Technologies; target of Rs 3165: Emkay Global Financial,"Emkay Global Financial's research report on Dixon TechnologiesDixon’s PAT for 3QFY23 was ~30% below consensus estimates. Sales declined 22% YoY and turned out to be the major disappointment. Consumer electronics and lighting sales declined by more than 35% YoY, and were the main segments that dragged down sales. Despite lower sales, margin came in at 4.6%, with all segments seeing better margin than in 3QFY22. Management indicated that value engineering, cost optimization and certain price hikes were the main margin drivers. FY23 sales guidance by Management has been further cut to Rs120-125bn from the Rs140-145bn guided a few months earlier. Sales guidance for FY23 at the start of the year was ~Rs170-180bn. We have built-in ~Rs120bn/Rs180bn revenue for FY23E/FY24E, with EBITDAM at ~4%. Our EPS for FY24E/FY25E stands at ~Rs71/Rs97.OutlookOur Dec-23 TP stands at Rs3,165/share, based on 35x (40x earlier, given lower growth rate in the medium term).For all recommendations report, click hereDisclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.Dixon Technologies - 27 -01-2023 - emkay",Dixon Technologies (India) Ltd.
"  January 27, 2023 / 10:50 PM IST  ","Hold Dixon Technologies, target of Rs 3770: Sharekhan","Sharekhan's research report on Dixon TechnologiesConsolidated Q3FY23 performance was below estimates as sales declined by 22% y-o-y. However, the margin improved y-o-y in all the segments. Net profit grew moderately by 12% y-o-y to Rs 52 crore. Management scaled down revenue target for FY23 due to slower growth in mobile division and low realization in TV segment. We see limited room for an upside from current price levels given expensive valuation post revenue and earnings downgrade. Although long-term prospects are bright, we await better entry point for investors.OutlookWe downgrade Dixon Technologies (Dixon) from Buy to Hold with a revised PT of Rs 3,770 following muted Q3FY23 and a cut in revenue guidance for FY23/FY24.For all recommendations report, click hereDisclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.Dixon Technologies - 27 -01-2023 - Khan",Dixon Technologies (India) Ltd.
"  January 27, 2023 / 05:30 PM IST  ","MC BudEx falls 3% dragged down by Dixon Technologies, Adani Ports","As bears gripped Dalal Street, Moneycontrol's Budget Sensitivity Index (MC BudEx) fell 3.04 percent on January 27 dragged down by infrastructure, manufacturing, and banking names. In comparison, Nifty and Sensex fell about 1.5 percent each.Top losers on the MC BudEx were Dixon Technologies, Adani Ports, IRB Infra, and Bank of Baroda. Of the total 30 stocks, Dabur India, ITC, Tata Power, and Mahindra & Mahindra were the only stocks that ended in the green.Electronics manufacturing services firm Dixon Technologies was the biggest loser, falling over 18 percent after the company cut its FY23 revenue guidance to Rs 12,200 crore ‐Rs 12,700 crore from Rs 15,000 crore.The company's revenue from operations fell 22 percent year-on-year to Rs 2,405 crore. ""We have lowered our guidance primarily due to a slowdown in the mobile business. There is a likelihood of FY24 revenue guidance to be lowered from Rs 19,000 crore,"" group CFO Saurabh Gupta told CNBC-TV18.Weak consumer demand and lower prices of pass-through inputs also led to revenue miss, said analysts. With Budget 2023 right around the corner, all eyes will be on how the Government plans to boost consumption in India.Several consumer companies part of the MC BudEx have highlighted weak demand trends in rural and semi-urban areas amid high retail inflation.Also Read Budget 2023: As discretionary demand dwindles, industry wish list runs longAdani Ports was the other big loser on the MC BudEx, declining over 15 percent. The stock has shed over 25 percent year-to-date. Adani Ports was followed by Bank of Baroda which closed 7.4 percent lower. Bank of Baroda was also the biggest loser on Nifty Bank, which ended down by 3.13 percent.""Participants were already facing challenges due to mixed global cues and caution ahead of the Union Budget and today's breakdown in markets has further added to worries,"" Ajit Mishra, VP - of Technical Research, Religare Broking said.Some part of India’s underperformance vis-à-vis global markets off late can be explained by the huge outperformance by India last year, believes Nishit Master, Portfolio Manager, Axis Securities. ""Markets are attempting to revert back to the mean,"" he said.Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.",Dixon Technologies (India) Ltd.
"  January 27, 2023 / 10:51 AM IST  ","Dixon Technologies tanks 18% in worst-ever fall on weak Q3, FY23 guidance cut","Electronics manufacturing services firm Dixon Technologies fell over 18 percent on January 27 morning after the company cut its FY23 revenue guidance to Rs 12,200 crore ‐Rs 12,700 crore from Rs 15,000 crore following a weak October-December quarter.At 10 am, the stock was quoting at Rs 2,740 a share on the National Stock Exchange, down 18.32 percent, its worst fall since September 18, 2017 when it made its market debut. Trading volumes at 1.9 million shares were about ten times the 20-day average volume of 1.4 lakh shares.Follow our live blog for all the market actionThe company's revenue from operations fell 22 percent year-on-year to Rs 2,405 crore while its net profit grew 13 percent to Rs 52 crore. Operating margins improved from 3.4 percent to 4.7 percent.Mobile business in the slow laneSpeaking to CNBC-TV18, group CFO Saurabh Gupta said, ""We have lowered our guidance primarily due to a slowdown in the mobile business. Export market has slowed. There is a likelihood of FY24 revenue guidance to be lowered from Rs 19,000 crore.""The company's consumer electronics segment revenue fell 39 percent YoY to Rs 864 crore. Lighting products' revenue also fell 39 percent YoY to Rs 263 crore. Mobile & EMS Division revenue fell 3 percent YoY and 43 percent sequentially to Rs 915 crore.Foreign brokerage firm Credit Suisse has downgraded the stock to ""neutral"" with the target cut to Rs 3,300 from Rs 4,500 a share. ""Results were disappointing, valuations leave limited upside. Mobile revenue to contract sequentially with stall in Motorola business,"" the firm said.Weak consumer demand and lower prices of pass-through inputs led to revenue miss, it added.Nuvama Institutional Equities has cut FY23-24 estimates by 35-20 percent after weak results. ""But. growth seems healthy despite these cuts (with 30 percent return on equity). Hence, we retain Buy with a target price of Rs 3,865,"" it said.Disclaimer: The views and investment tips expressed by experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.​​​​​​​​​​​​​",Dixon Technologies (India) Ltd.
"  January 29, 2023 / 07:08 PM IST  ",Buy Dr Reddy's Laboratories; target of Rs 5210: ICICI Direct,"ICICI Direct's research report on Dr Reddy's LaboratoriesDr Reddy’s (DRL) portfolio includes pharmaceutical generics, APIs, custom pharmaceutical services, biosimilar and complex formulations. Revenue breakup Q2FY23: US (44%), India (19%), Russia and CIS (13%), Europe (7%), RoW (7%), PSAI (10%) • It has 13 formulation facilities, nine API manufacturing facilities, one biologics facility and several R&D centres across the globe.OutlookWe value Dr Reddy’s at Rs 5210 i.e. 21x FY25E EPS of Rs 241.8+ NPV of Rs 131 for gRevlimid.For all recommendations report, click hereDisclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.Dr Reddy's Laboratories - 27 -01-2023 - ic",Dr. Reddy's Laboratories Ltd.
"  January 27, 2023 / 10:51 PM IST  ","Buy Dr. Reddy’s Laboratories, target of Rs 5460: Sharekhan","Sharekhan's research report on Dr. Reddy’s LaboratoriesDr. Reddy’s Laboratories (DRL) continued to register strong numbers in Q3FY2023 also, led by even stronger growth in the US and recovery in the other markets. US revenue growth was driven by new product launches, increase in volumes, and favorable forex movement; partly offset by price erosion. Consolidated revenues grew by 27.2% y-o-y to Rs. 6,789.8 crore; gross margins improved by 452 bps y-o-y to 70.5% and OPM improved by 589 bps y-o-y to 28.7%; PAT grew by a strong 75.4% y-o-y to Rs. 1,243.9 crore aided by strong growth in operating profits with improved new product launches and favorable products mix, despite increase in interest cost and taxes y-o-y.OutlookThe stock is currently trading at an attractive valuation of 14.5x/12.4x its FY2024E/25E. We maintain our Buy recommendation on the stock with unchanged PT of Rs. 5,460.For all recommendations report, click hereDisclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.Dr. Reddy’s Laboratories - 27 -01-2023 - khan",Dr. Reddy's Laboratories Ltd.
"  January 27, 2023 / 10:02 AM IST  ","Another great quarter for Dr Reddy’s, but is it sustainable?","                        Highlights

	Q3 benefits from g-Revlimid sales in the US & biosimilar sales in Russia
	India business lags industry but work-in-progress for increase in chronic portfolio
	Key risk is intensification of competition in the US and Indian markets
	Key watch is filing of Rituximab in US and Europe markets

Dr Reddy’s (CMP: Rs 4,201; Market cap: Rs 69,956 crore) posted strong results for Q3FY23, backed by the traction in generic version of Revlimid (g-Revlimid) and an institutional tender win in the Russian market.

While some of...
                    ",Dr. Reddy's Laboratories Ltd.
"  January 27, 2023 / 09:51 AM IST  ",Dr Reddy’s Q3 consolidated profit jumps 77%; what should investors do with the stock?,"Dr Reddy's Laboratories share price will remain in focus on January 27 after company announced its December quarter results on Wednesday.Pharma major Dr Reddy's Laboratories on January 25 reported a 77 percent growth in consolidated net profit at Rs 1,247 crore for the quarter ended December 31, 2022 as against Rs 707 crore a year ago. On a sequential basis, the profit grew 12 percent.The Hyderabad-based drug maker also reported a 27 percent increase in consolidated revenue at Rs 6,770 crore as against Rs 5,320 crore in the year-ago period, while it was up 7 percent sequentially.Catch all the market action on our live blogHere is what brokerages have to say about stock and the company post December quarter earnings:MacquarieResearch house has kept ‘Outperform’ rating on the stock with a target at Rs 4,915 per share as Q3 revenue/EBITDA/PAT beat estimates by 9 percent/37 percent/35 percent, respectively.Macquarie raises FY23 earnings estimates by 8 percent, while largely maintain FY24E/25 earnings estimates.Capital deployment priorities are clear, but have yet to see any firm action, reported CNBC-TV18.Morgan StanleyBroking house has kept ‘Overweight’ rating with target at Rs 5,099 per share.The strong Q3 driven largely by Revlimid and should continue for next several quarters.The core business is stable, while M&A is a focus area given strong balancesheet, reported CNBC-TV18.Nirmal BangMaintain 'Accumulate' rating on the stock with a revised target price of Rs 4,745Believe that the company has reported USD 120-130mn Revlimid revenue (with ~75% margin), almost double than the estimateExcluding Revlimid, do not expect the company to achieve 25% guided EBITDA margin on an annualized basis, at least in the near to medium termDisclaimer: The views and investment tips expressed by experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.",Dr. Reddy's Laboratories Ltd.
"  January 28, 2023 / 08:49 PM IST  ","Buy Maruti Suzuki India, target of Rs 10,965: Sharekhan","Sharekhan's research report on Maruti Suzuki IndiaThis was the consecutive second quarter when MSIL has registered EBIDTA margin above 9% backed by favourable product mix and gross margin expansion. Management bets on launches of SUVs and CNG variants to regain its market share. The company continues to strengthen its distribution network through increasing presence penetration. Backed by a strong response to its SUVs, the management is looking for a leadership position in SUV segment in coming years.OutlookWe reiterate our Buy rating on Maruti Suzuki India Limited (MSIL), with an unchanged PT of Rs. 10,965, factoring gains in market shares through refreshed and new launches. stock trades at P/E of 22.2x and EV/EBITDA of 16.3x on FY2025E earnings estimates.For all recommendations report, click hereDisclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.Maruti Suzuki India - 27 -01-2023 - khan",Maruti Suzuki India Ltd.
"  January 28, 2023 / 08:48 PM IST  ","Buy Maruti Suzuki; target of Rs 10,500: Motilal Oswal","Motilal Oswal's research report on Maruti SuzukiMSIL reported a strong beat in 3QFY23, driven by better mix (8% beat on ASPs) and higher other income. Recently launched products to reflect in P&L from 1QFY24; commodity price benefit largely reflected in 3QFY23; and the impact of adverse JPY is expected to reflect from 1QFY24. We expect continued improvement in performance and response to new products to act as catalysts for the stock.OutlookWe upgrade FY23 EPS estimates by 14% to reflect the benefit of mix and higher ‘other income’, but reiterate our FY24 estimates as the mix benefit is offset by the Fx impact. We reiterate our Buy rating with a TP of INR10,500.For all recommendations report, click hereDisclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.Maruti Suzuki - 27 -01-2023 - moti",Maruti Suzuki India Ltd.
"  January 27, 2023 / 07:34 AM IST  ","Hot Stocks: Here's why 10-17% return possible in Maruti Suzuki, Persistent Systems, Carborundum Universal in short-term","On the weekly timeframe, we can spot that the prices have taken support from the 50 percent Fibonacci retracement level of the prior advance from 16,747 (September 2022) till 18,887 (November 2022), which is again in sync with the bearish trendline which shows change in the polarity.Nifty on daily charts we can spot that the prices are trading below the 20-day SMA (simple moving average). However still it is trading in a range of 17,770 – 18,265 levels since last few weeks.The momentum indicator RSI (relative strength index), plotted on the weekly timeframe is moving near 50 level confirming the lack of momentum.The Nifty has immediate resistance placed at 18,038 (20-day SMA) followed by 18,265 (key resistance) levels. The downside support for the index is placed at 17,770 (swing low) followed by 17,600 (key support).Based on the overall trend and indications from indicators, it is expected that the Nifty will stay in rangebound territory of 17,770 – 18,265 level. While a breach below the level of 17,770 can drag the prices lower till 17,600.Here are three buy calls for next 2-3 weeks:Maruti Suzuki: Buy | LTP: Rs 8,784 | Stop-Loss: Rs 8,440 | Target: Rs 9,765 | Return: 11 percentThe stock ended its correction at 50 percent Fibonacci retracement (Rs 8,076) of previous advance from Rs 6,536 – 9,769 and started moving up since last 5 weeks on the weekly charts indicating positive undertone of the stock.On the daily charts the stock is forming higher top higher bottom formation on swing basis. Also the stock has formed CIP (Change in Polarity) near Rs 8,076 mark.The stock consistently sustaining above its 20-day SMA since last 2 weeks with volume confirmation indicating strong demand zone created near that point.The prices have given a Bollinger band squeeze breakout on the up side indicating volatility rises on a positive side.The weekly relative strength index (RSI) has failed to reach lower levels (swing failure), indicating that the upward momentum of the stock is increasing.Going ahead we expect the prices to go higher till Rs 9,765 level where stop-loss must be Rs 8,440 on the closing basis.Persistent Systems: Buy | LTP: Rs 4,594 | Stop-Loss: Rs 4,200 | Target: Rs 5,385 | Return: 17 percentThe stock has bottomed out near Rs 3,100 level after forming Double Bottom formation on the weekly charts in September 2022 and since then it is maintaining Higher Top Higher Bottom formation indicating strong bullish undertone of the stock.In the current week, the stock is giving breakout of Cup & Handle pattern with volume confirmation which indicates strong strength to the upside.The stock on the daily timeframe is consistently trading near upper Bollinger Band which points towards the rising volatility for an up move.The momentum indicator RSI on the weekly timeframe has shown range shift pointing towards rising momentum of the prices.Going ahead we expect the prices to move higher till the level of Rs 5,385 where the stop-loss must be Rs 4,200 on the closing basis .Carborundum Universal: Buy | LTP: Rs 941.45 | Stop-Loss: Rs 860 | Target: Rs 1,035 | Return: 10 percentThe stock took strong support at 20-month SMA and sustaining at 11-month high. This shows overall bullish undertone of the prices.The stock has given a breakout of Cup & Handle pattern and sustaining above that breakout. This points towards the continuation of trend in the direction of breakout.The stock has sustained above key moving averages of 50 and 200-day EMA (exponential moving average) which confirms the intact uptrend.The uptrend is accompanied by higher volumes showing long built up in the stock.The momentum indicator RSI has sustained well above 60 mark on the weekly timeframe and moving upward reflecting strong momentum.Going ahead we expect the prices to move Higher till Rs 1,035 where the stop-loss must be Rs 860 on the closing basis.Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.",Maruti Suzuki India Ltd.
"  January 29, 2023 / 07:08 PM IST  ",Hold Pidilite Industries; target of Rs 2535: ICICI Direct,"ICICI Direct's research report on Pidilite IndustriesPidilite is a market leader in the adhesive and sealants business. The company’s consumer & bazaar (C&B) segment (adhesives & sealants, construction & paint chemical, art & craft materials) contributes 80% to topline while the B2B segment (industrial adhesive, resins and pigments) contributes ~20% to topline • Has 4898+ distributors, strong balance sheet (RoE, 19%, RoCE, 22%).OutlookWe maintain our HOLD rating on the stock. We roll over our valuation on FY25E and value the stock at 62x P/E of FY25E EPS with a revised target price of Rs 2535.For all recommendations report, click hereDisclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.Pidilite Industries - 27 -01-2023 - ic",Pidilite Industries Ltd.
"  January 27, 2023 / 10:54 PM IST  ","Hold Pidilite Industries, target of Rs 2515: Sharekhan","Sharekhan's research report on Pidilite IndustriesPidilite Industries Limited’s (Pidilite’s) Q3FY2023 performance was muted with 5% y-o-y revenue growth, while EBITDA margin fell by 272 bps y-o-y to 16.5% due to higher input prices, weaker currency, and high-cost inventory. PAT declined by 14% y-o-y. VAM prices have corrected to $1,200 per tonne from highs of $2,500 per tonne (consumption price was at $2,000 per tonne in Q3). The company expects EBIDTA margins to sequentially improve (likely to touch 20% in Q4). Q3 performance was impacted by inventory pile up by stockiest in the base quarter. Management has seen demand remaining resilient in the Tier 1,2 & 3 market while rural markets continue to reel under pressure. Management retained its targets of double digit volume growth in the medium term.OutlookThe stock trades at 62.6x and 52.5x its FY2024E and FY2025E earnings. In view of premium valuations and near term demand headwinds. We retain Hold with a revised price target of Rs. 2,515.For all recommendations report, click hereDisclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.Pidilite Industries - 27 -01-2023 - khan",Pidilite Industries Ltd.
"  January 27, 2023 / 09:58 AM IST  ",Pidilite: Why we stay neutral despite raw material tailwinds,"                        Highlights:

	Pricing-led growth, volume remains elusive
	Margins likely to recover with correction in raw material prices
	Competitive intensity likely to increase
	Remain neutral, given the valuation captures most of the positives

The Q3FY2023 performance of Pidilite Industries (CMP: Rs2316) was below market expectations. The demand remained resilient in the Tier 1, 2 & 3 markets, while rural markets were impacted by higher inflation. VAM (vinyl acetate monomer) prices have corrected significantly from their highs and we expect margins to recover in the March23 quarter.

Key...
                    ",Pidilite Industries Ltd.
"  January 28, 2023 / 08:48 PM IST  ",Buy SBI Cards and Payment Services; target of Rs 960: Motilal Oswal,"Motilal Oswal's research report on SBI Cards and Payment ServicesSBICARD reported a weak quarter as higher provisions dragged down net earnings and PPoP came in slightly below our estimate. PAT grew 32% YoY to INR5.1b (13% miss). Margins declined 70bp QoQ to 11.6% in 3QFY23 due to a lower revolver mix (24%) and a higher cost of funds. Growth in spends was healthy at 11% QoQ, with corporate spends up 25% and retail spends up 7% QoQ. GNPA/NNPA ratios increased by 8bp/2bp QoQ to 2.22%/0.8%. PCR was stable at ~64%. RoA/RoE came in at 4.8%/22.0%.OutlookWe cut our estimates by 5-7% to factor in lower NII and slightly higher provisions. We estimate SBICARD to deliver a 34% earnings CAGR over FY23– 25, leading to RoA/RoE of 6.5%/27.9%. Maintain Buy with a TP of INR960.For all recommendations report, click hereDisclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.SBI Cards and Payment Services - 27 -01-2023 - moti",SBI Cards and Payment Services Ltd.
"  January 27, 2023 / 10:22 AM IST  ",Tata Elxsi rises after Q3 profit grows 29%; Morgan Stanley still sees 14% downside,"Tata Elxsi share price edged higher during early trade on January 27 despite weak market conditions. At 09:53 am, the stock quoted Rs 6,657.50, up Rs 60.70, or 0.92 percent.The company reported its earnings for Oct-Dec wherein net profit came in at Rs 194.68 crore, up 28.97 percent from Rs. 150.95 crore in December 2021. EBITDA came in at Rs. 265.99 crore in the given quarter, up 22.38 percent from Rs 217.35 crore in a year ago.The company has reported EPS of Rs. 31.26 for the period ended December 31, 2022 as compared to Rs. 27.98 for the period ended September 30, 2022.It also reported total income of Rs 836.87 crore during the period ended December 31, 2022 as compared to Rs 641.9244 crore during the period ended December 31, 2021.Catch all the market action on our live blogHowever, global research and broking firm Morgan Stanley has an underweight rating on the stock with target at Rs 5,800 per share, a down side of 14 percent from current market price.""Embedded Product Design (EPD) business slowed for fifth straight quarter affected by furloughs and project deferments while commentary on outlook is balanced. Cost normalisation and ESOP costs should keep margin expectations in check,"" it said.Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.​",Tata Elxsi Ltd.
"  January 27, 2023 / 09:23 AM IST  ","Tata Elxsi Standalone December 2022 Net Sales at Rs 817.74 crore, up 28.69% Y-o-Y","Net Sales at Rs 817.74 crore in December 2022 up 28.69% from Rs. 635.41 crore in December 2021.Quarterly Net Profit at Rs. 194.68 crore in December 2022 up 28.97% from Rs. 150.95 crore in December 2021.EBITDA stands at Rs. 265.99 crore in December 2022 up 22.38% from Rs. 217.35 crore in December 2021.Tata Elxsi EPS has increased to Rs. 31.26 in December 2022 from Rs. 24.24 in December 2021.Tata Elxsi shares closed at 6,597.20 on January 25, 2023 (NSE) and has given -22.65% returns over the last 6 months and -6.30% over the last 12 months.",Tata Elxsi Ltd.
"  January 29, 2023 / 05:36 PM IST  ",Buy Tata Motors; target of Rs 515: Emkay Global Financial,"Emkay Global Financial's research report on Tata MotorsQ3FY23 consol. EBITDA surged 43% YoY to Rs96.4bn, above our estimate of Rs74.3bn, backed by better margins in JLR and standalone divisions. JLR’s strong performance was driven by better volumes and mix, whereas standalone performance was led by better pricing. Consol. revenue grew by 23% to Rs884.9bn, standing 6% above our estimates due to better revenues in JLR and standalone divisions. JLR’s order book is strong, at ~215,000 units. Models such as new generation RR/RR Sport and Defender form 74% of the order book which should lead to product-mix improvement ahead. Factoring-in the strong Q3 performance, we increase FY23E consol. EBITDA by 14%.OutlookWe maintain our positive stance on expectations of a sales upcycle across segments and aggressive cost savings. We reaffirm BUY on the stock, with SOTP-based TP of Rs515/share now (Rs485 earlier), based on FY25 estimates (Dec-24E earlier).For all recommendations report, click hereDisclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.Tata Motors - 27 -01-2023 - emkay",Tata Motors Ltd.
"  January 27, 2023 / 10:51 PM IST  ","Buy Tata Motors, target of Rs 516: Sharekhan","Sharekhan's research report on Tata MotorsConsolidated Q3FY23 results beat expectations, led by strong operational performance, across its key verticals. Consolidated EBITDA was ahead of our estimates by 33%. Overall performance and FCF are expected to improve gradually, driven by a positive business outlook, new launches, easing chips shortage situation, cooling commodity prices, and favourable macro-economic outlook. Management maintained its long-term targets with a caution on inflation and geopolitical situations. TAMO’s focus on EVs continues to grow multifold in Q3FY23; electric CVs are getting ready for the next leg of growth.OutlookWe maintain Buy with an unchanged PT of Rs. 516, driven by continued growth momentum in volumes and operational improvement across business verticals and geographies.For all recommendations report, click hereDisclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.Tata Motors - 27 -01-2023 - khan",Tata Motors Ltd.
"  January 27, 2023 / 11:05 AM IST  ","Tata Motors Q3 FY23: A strong quarter for both India, international businesses","                        Highlights

	New products and the easing of chip supply helped JLR’s operating margin
	Softening of raw material prices and higher realisation helped domestic business margins
	Aggressive focus on EVs a key trigger for re-rating
	Both JLR and domestic business expected to perform well on the back of strong demand
	SOTP valuation suggests stock has upside potential
With the waning impact of semiconductor chip shortage and the softening of raw material prices, Tata Motors (TML; CMP: Rs 419; Market cap: Rs 1,50,100 crore) posted a strong...
                    ",Tata Motors Ltd.
"  January 27, 2023 / 09:30 AM IST  ","Tata Motors races on profit after 7 quarters, what should you do with the stock?","Tata Motors raced over 7 percent on January 27 after December quarter earnings beat estimates.On January 25, the company reported a consolidated net profit of Rs 2,957.71 crore for the quarter ended December 2022, against a loss of Rs 1,516.14 crore in the same quarter last year.The company posted profit after recording losses for seven consecutive quarters.At 9:30 am, the stock was quoting at Rs 448.20 apiece on the National Stock Exchange, up by 7 percent. Trading volumes were 15.2 million shares.Revenue from operations came in at Rs 88,488.59 crore, up 22.51 percent from Rs 72,229.29 crore in the same quarter last year, Tata Motors said in an exchange filing.Catch all the market action on our live blogHere is what brokerages have to say about stock and the company post December quarter earnings:SharekhanMaintain 'Buy' with an unchanged Price Target of Rs 516.Company is witnessing robust demand and is expected to deliver better operational efficiencies, aided by aggressive launches, market positioning, product differentiation, cost savings, and investments in research and development (R&D).Expect operational performance to improve strongly in Q4FY23E and FY24E, as supply constraints are expected to ease gradually, while demand remains strong for both JLR and domestic operations.Domestic CV and PV segments are expected to remain healthy because of new launches and operating leverage benefits.NomuraResearch firm has kept ‘Buy’ rating on the stock with a target at Rs 508 per share.The Q3 margin improves across segments. JLR to benefit from rising chip supply and India CV strategy to reduce disc working well.Company management says JLR Q4 volumes may be 85,000 & improve further in FY24.Nomura maintains volume estimates for JLR for FY23-25 at 3.67 lakh/4.70 lakh/4.78 lakh and maintain EBITDA margin estimates for JLR for FY23-25 at 10.3 percent/14.1 percent/14 percent, reported CNBC-TV18.JefferiesBrokerage house has maintained ‘Buy’ rating on the stock and raised the target price to RS 565 per share.The Q3 EBITDA grew to a 7-quarter high and was 25 percent above the estimates, while EBITDA/vehicle rose at JLR & India CVs led by better mix and pricing.JLR maintained its Q4 guidance & expects chip constraints to ease gradually.The company has strong order book with 74 percent of orders for new RR, RR-sport & defender.Jefferies expect lower net loss in FY23 & raise FY24-25 EPS by 3-5 percent, reported CNBC-TV18.Disclaimer: The views and investment tips expressed by experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.",Tata Motors Ltd.
"  January 29, 2023 / 07:08 PM IST  ",Hold Torrent Pharmaceuticals; target of Rs 1720: ICICI Direct,"ICICI Direct's research report on Torrent PharmaceuticalsIncorporated in 1959, Torrent remains a key play in branded generics (~60% of sales) with strong India franchise and growing exports traction. Revenues – India including CRAMs (59.8%), Brazil (8.3%), US (11.3%) and Germany (10.4%) • Torrent is the eighth largest domestic player and is ranked in top 10 for CVS, CNS, V&M, GI and anti-diabetes therapies in India.OutlookWe maintain HOLD as the current price factors in potential upside from the branded business. Valued at Rs 1720 i.e. 32x FY25E EPS of Rs 53.8.For all recommendations report, click hereDisclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.Torrent Pharmaceuticals - 27 -01-2023 - ic",Torrent Pharmaceuticals Ltd.
"  January 27, 2023 / 11:54 PM IST  ","Vedanta Standalone December 2022 Net Sales at Rs 15,832.00 crore, down 2.19% Y-o-Y","Net Sales at Rs 15,832.00 crore in December 2022 down 2.19% from Rs. 16,187.00 crore in December 2021.Quarterly Net Profit at Rs. 4,684.00 crore in December 2022 down 27.64% from Rs. 6,473.00 crore in December 2021.EBITDA stands at Rs. 6,337.00 crore in December 2022 down 28.17% from Rs. 8,822.00 crore in December 2021.Vedanta EPS has decreased to Rs. 12.59 in December 2022 from Rs. 17.40 in December 2021.Vedanta shares closed at 326.25 on January 25, 2023 (NSE) and has given 34.04% returns over the last 6 months and -0.59% over the last 12 months.",Vedanta Ltd.
"  January 27, 2023 / 04:58 PM IST  ","Vedanta Q3 result: Net profit plunges 41% to Rs 2,464 crore; announces dividend of Rs 12.5","Vedanta Limited on January 27 reported a 40.81 percent drop in consolidated net profit for the quarter ended December 2022 at Rs 2,464 crore against Rs 4,164 crore in the same quarter last year.The revenue from operations came in at Rs 33,691 crore, down 0.01 percent from Rs 33,697 crore in the corresponding quarter a year ago, the company said in an exchange filing.The Board of Directors of the Company also approved the fourth interim dividend of Rs 12.50 per equity share amounting to Rs 4,647 crore. The record date for the payment is February 4, 2023.“We have delivered a strong set of financial results and steady operational performance in a challenging macroeconomic environment,” Chief Executive Officer Sunil Duggal said.“We have approved plans for another 941 MW RE power under group captive RE power development program. I am also happy to share that Vedanta and Hindustan Zinc Limited Boards have taken a strategic initiative to consolidate Zinc International under Hindustan Zinc.”The company said its quarterly alumina production decreased by 2 percent quarter on quarter (QoQ) to 443 kilotonnes (kt) due to maintenance activities in calciners. Karnataka saleable iron ore production increased by 32 percent QoQ to 1.4mn tonnes. Pig iron production was higher by 66 percent QoQ as the second quarter was impacted by the shut down of smaller blast furnace.Saleable production of steel was of 306kt, lower by 6 percent QoQ due to maintenance activities in blast furnace.The company said it continues to maintain healthy cash and cash equivalents of Rs 23,474 crore as on 31st Dec 2022.",Vedanta Ltd.
